Open Access

Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model

  • Authors:
    • Daniel Cervantes‑Garcia
    • Adriana Guadalupe Cuellar‑Juarez
    • Gissela Borrego‑Soto
    • Augusto Rojas‑Martinez
    • Liseth Rubi Aldaba‑Muruato
    • Eva Salinas
    • Javier Ventura‑Juarez
    • Martin Humberto Muñoz‑Ortega
  • View Affiliations

  • Published online on: October 12, 2017     https://doi.org/10.3892/mmr.2017.7785
  • Pages: 9431-9440
  • Copyright: © Cervantes‑Garcia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Liver fibrosis occurs in the presence of continuous insults, including toxic or biological agents. Novel treatments must focus on ceasing the progression of cellular damage, promoting the regeneration of the parenchyma and inhibition of the fibrotic process. The present study analyzed the effect of bone morphogenetic protein (BMP)‑7 gene therapy with or without co‑treatment with doxazosin in a model of liver cirrhosis in hamsters. The serum alanine aminotransferase, aspartate aminotransferase and albumin levels were analyzed spectrophotometrically. Tissue hepatic samples were analyzed by hematoxylin and eosin for parenchymal structure and Sirius red for collagen fiber content. BMP‑7 and α‑smooth muscle actin (SMA)‑positive cells were detected by immunohistochemistry. BMP‑7 and collagen type I content in hepatic tissue were analyzed by western blotting, and tissue inhibitor of metalloproteinases (TIMP)‑2 and matrix metalloproteinase (MMP)‑13 expression levels were detected by reverse transcription‑quantitative polymerase chain reaction. The present study detected a significant reduction of collagen type I deposits in the group treated with adenoviral‑transduction with BMP‑7 and doxazosin. In animals with BMP‑7 and doxazosin therapy, α‑SMA‑positive cells were 31.7 and 29% significantly decreased compared with animals with placebo, respectively. Adenoviral‑BMP‑7 transduction and/or doxazosin treatments actively induced decrement in type I collagen deposition via increased MMP‑13 and reduced TIMP‑2 expression. In conclusion, the adenovirus‑BMP‑7 gene therapy and the doxazosin therapy are potential candidates for the diminution of fibrosis in the liver, although combination of both therapies does not improve the individual anti‑fibrotic effect once cirrhosis is established.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 16 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cervantes‑Garcia D, Cuellar‑Juarez AG, Borrego‑Soto G, Rojas‑Martinez A, Aldaba‑Muruato LR, Salinas E, Ventura‑Juarez J and Muñoz‑Ortega MH: Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model. Mol Med Rep 16: 9431-9440, 2017
APA
Cervantes‑Garcia, D., Cuellar‑Juarez, A.G., Borrego‑Soto, G., Rojas‑Martinez, A., Aldaba‑Muruato, L.R., Salinas, E. ... Muñoz‑Ortega, M.H. (2017). Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model. Molecular Medicine Reports, 16, 9431-9440. https://doi.org/10.3892/mmr.2017.7785
MLA
Cervantes‑Garcia, D., Cuellar‑Juarez, A. G., Borrego‑Soto, G., Rojas‑Martinez, A., Aldaba‑Muruato, L. R., Salinas, E., Ventura‑Juarez, J., Muñoz‑Ortega, M. H."Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model". Molecular Medicine Reports 16.6 (2017): 9431-9440.
Chicago
Cervantes‑Garcia, D., Cuellar‑Juarez, A. G., Borrego‑Soto, G., Rojas‑Martinez, A., Aldaba‑Muruato, L. R., Salinas, E., Ventura‑Juarez, J., Muñoz‑Ortega, M. H."Adenoviral‑bone morphogenetic protein‑7 and/or doxazosin therapies promote the reversion of fibrosis/cirrhosis in a cirrhotic hamster model". Molecular Medicine Reports 16, no. 6 (2017): 9431-9440. https://doi.org/10.3892/mmr.2017.7785